Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.
2.
3.

Advances in the treatment of hepatitis C virus infection.

Thomas DL.

Top Antivir Med. 2012 Apr-May;20(1):5-10.

4.
5.

Management of the hematologic complications of hepatitis C therapy.

Sulkowski MS.

Clin Liver Dis. 2005 Nov;9(4):601-16, vi. Review.

PMID:
16207566
6.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
7.

Management of side-effects.

Rosa I.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S69-74. doi: 10.1016/S2210-7401(11)70011-0.

PMID:
22248698
8.

Anemia management in patients with chronic viral hepatitis C.

Hynicka LM, Heil EL.

Ann Pharmacother. 2013 Feb;47(2):228-36. doi: 10.1345/aph.1R513. Epub 2013 Feb 5. Review.

PMID:
23386076
9.

Hematologic disorders associated with hepatitis C virus infection and their management.

Dieterich DT, Spivak JL.

Clin Infect Dis. 2003 Aug 15;37(4):533-41. Epub 2003 Aug 1.

PMID:
12905138
10.

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC.

J Hepatol. 2012 Feb;56(2):455-63. doi: 10.1016/j.jhep.2011.08.006. Epub 2011 Aug 30. Review.

11.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
12.
13.

Use of growth factors with antiviral therapy for chronic hepatitis C.

Curry MP, Afdhal NH.

Clin Liver Dis. 2005 Aug;9(3):439-51, vii. Review.

PMID:
16023976
14.

Approach to the treatment-naïve patient with HCV genotype 1 infection.

Muir AJ.

Infect Dis Clin North Am. 2012 Dec;26(4):893-901. doi: 10.1016/j.idc.2012.08.012. Review.

PMID:
23083822
15.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
16.

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

Mulhall BP, Younossi Z.

J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S23-7.

PMID:
15597024
17.

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.

Seden K, Back D.

Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. doi: 10.1097/COH.0b013e32834b54dc. Review.

PMID:
22001895
18.

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

Sheridan DA, Neely RD, Bassendine MF.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):10-6. doi: 10.1016/j.clinre.2012.07.002. Epub 2012 Sep 5. Review.

PMID:
22959093
19.

[Managing psychiatric side effects of antiviral therapy in chronic hepatitis C].

Schäfer A, Scheurlen M, Kraus MR.

Z Gastroenterol. 2012 Oct;50(10):1108-13. doi: 10.1055/s-0031-1281682. Epub 2012 Oct 11. Review. German.

PMID:
23059806
20.

Management and treatment of chronic hepatitis C in HIV patients.

Barreiro P, Vispo E, Labarga P, Soriano V.

Semin Liver Dis. 2012 May;32(2):138-46. doi: 10.1055/s-0032-1316469. Epub 2012 Jul 3. Review.

PMID:
22760653

Supplemental Content

Support Center